

Supplementary Table S2. Summary of pharmacokinetics of 600 mg TPST-1120 twice daily as a single agent and in combination with nivolumab after single dose or at steady state (cycle 1 day 8)

| Parameter | 600 mg BID Monotherapy + Combination | |
|--|--------------------------------------|-----------------|
| | n | Mean (CV%) |
| Single dose | | |
| AUC _{0-τ} (ng*h/mL) | 15 | 12,784.7 (58.7) |
| C _{max} (ng/mL) | 15 | 3,634.7 (52.8) |
| T _{max} (h) | 15 | 2 ^a |
| Half-life (h) | 11 | 4.25 (98.4) |
| CL/F (L/h) | 11 | 46.44 (56.6) |
| Vz/F (L) | 11 | 296.5 (154.2) |
| Steady state | | |
| AUC ₀₋₁₂ (ng*h/mL) | 13 | 13,444.6 (49.9) |
| C _{max} (ng/mL) | 13 | 3,675.4 (47.9) |
| T _{max} (h) | 13 | 1 ^a |
| CL/F (L/h) | 13 | 51.4 (32.6) |
| R _{ac} (AUC) | 13 | 1.08 |

Abbreviations: AUC_{0- τ} , area under the concentration time curve, from time 0 to the last time point with a quantifiable plasma concentration (C1D1 single dose only); AUC₀₋₁₂, area under the concentration time curve from time 0 to 12 hours; C_{max}, maximum observed concentration in plasma; CL/F, apparent oral clearance; CV, coefficient of variation; R_{ac}, Ratio of accumulation of drug at steady state compared to single dose; T_{max}, time of maximum observed concentration in plasma; Vz/F, apparent oral volume of distribution.

^aMedian value.